Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric ertugliflozin placebo-controlled study in type 2 diabetes mellitus
2017-003455-35Phase 3Unknown
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ertugliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in hemoglobin A1C at 24 weeks. Status: unknown.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-003455-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003455-35.